Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222259
Post hoc analysis from ORAL Surveillance observes higher major adverse cardiovascular events (MACE) risk with tofacitinib vs TNFi in patients with RA and history of atherosclerotic cardiovascular disease (ASCVD).
The tofacitinib post-authorisation study that evaluated the relative risk of adjudicated MACE and malignancies with tofacitinib versus TNFi in patients with RA aged ≥50 years with ≥1 additional CV risk factor indicated an increased risk of MACE with tofacitinib vs TNFi.
This post hoc analysis of the data, by Charles-Schoeman, et al. further evaluates risk of MACE with tofacitinib vs TNFi in the ORAL Surveillance overall population, and in patients with or without a history of ASCVD.